23andMe To Present Preliminary Efficacy And Biomarker Data For 23ME-00610 At The 2024 ASCO Annual Meeting
23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced that two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, have been accepted for poster